Current Liabilities decreased faster than Evaxion A's Cash & cash equivalent, this led to improvement in Evaxion A's Quick Ratio to 122.28, above Evaxion A average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 54 other companies have achieved higher Quick Ratio than Evaxion A in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 0 to 502.

Explain Quick Ratio?
How much Cash & cash equivalents EVAX�s has?
What are EVAX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

EVAX Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	19.5 %	-33.23 %	16.46 %	-33.23 %	-98.13 %
Y / Y Cash & cash equivalent Change	210.12 %	290.36 %	77.73 %	290.36 %	17.1 %
Quick Ratio MRQ	122.28	4.35	84.84	4.35	47.12
EVAX's Total Ranking	# 502	# 0	#	#	#
Seq. Current Liabilities Change	-96.45 %	2805.98 %	-96.56 %	3262.89 %	-98.01 %
Seq. Cash & cash equivalent Change	0 %	48.84 %	-32.81 %	210.12 %	25.87 %

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 55
Healthcare Sector	# 247
Overall Market	# 502

Quick Ratio Statistics
High	Average	Low
7.63	2.79	0.74
(Dec 31 2021)		(Dec 31 2024)

Financial Statements
Evaxion A's Current Liabilities	$ 0 Millions	Visit EVAX's Balance sheet
Evaxion A's Cash & cash equivalent	$ 23 Millions	Visit EVAX's Balance sheet
Source of EVAX's Sales		Visit EVAX's Sales by Geography

Cumulative Evaxion A's Quick Ratio

EVAX's Quick Ratio for the trailling 12 Months

EVAX Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-32.24 %	-55.25 %	-45.52 %	-45.61 %	-36.25 %
Y / Y Cash & cash equivalent TTM Growth	202.75 %	156.86 %	89.92 %	70.47 %	3.93 %
Quick Ratio TTM	7.71	6.3	3.82	3.33	1.73
Total Ranking TTM	# 4273	# 0	#	#	#
Seq. Current Liabilities TTM Growth	0.28 %	-19.43 %	0.19 %	-16.29 %	-33.78 %
Seq. Cash & cash equivalent TTM Growth	22.63 %	33.05 %	15.02 %	61.33 %	4.04 %

Quick ratio ranking by company, industry and sector >> Back to EVAX Financial Strength Comparisons >> Go to Compare EVAX Quick Ratio to its Competitors

On the trailing twelve months basis EVAX Cash & cash equivalent more than doubled by 210.12 % in Q4 2025 year on year, faster than Current Liabilities, this led to increase in in Evaxion A's Quick Ratio to 7.71, above EVAX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 153 other companies have achieved higher Quick Ratio than Evaxion A. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 0 to 4273.

Explain Quick Ratio?
How much Cash & cash equivalents EVAX�s has?
What are EVAX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 154
Healthcare Sector	# 958
Within the Market	# 4273

trailing twelve months Quick Ratio Statistics
High	Average	Low
7.63	2.57	0.74
(Dec 31 2021)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Evaxion A	122.28	$ 23.234 Millions	$ 0.190 Millions
Instil Bio Inc	97.73	$ 76.129 Millions	$ 0.779 Millions
Redwoods Acquisition Corp	65.84	$ 7.177 Millions	$ 0.109 Millions
Lexeo Therapeutics Inc	37.43	$ 181.767 Millions	$ 4.856 Millions
Inhibikase Therapeutics Inc	34.12	$ 178.764 Millions	$ 5.239 Millions
Palisade Bio Inc	28.77	$ 133.385 Millions	$ 4.636 Millions
Tectonic Therapeutic Inc	26.26	$ 253.798 Millions	$ 9.666 Millions
Apogee Therapeutics Inc	26.17	$ 730.192 Millions	$ 27.906 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.